OTCMKTS:IMMVF - Immunovia AB (publ) Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$18.20
+0.30 (1.20%)
Get New Immunovia AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMMVF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMMVF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Immunovia AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.20.

Buy

The current consensus among 1 contributing investment analysts is to buy stock in Immunovia AB (publ).

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/22/2020DanskeInitiated CoverageBuy
i
(Data available from 6/16/2016 forward)
Immunovia AB (publ) logo
Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.
Read More

Today's Range

Now: $18.20
$18.20
$18.20

50 Day Range

MA: N/A

52 Week Range

Now: $18.20
$0.84
$2.00

Volume

N/A

Average Volume

12,942 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunovia AB (publ)?

The following equities research analysts have issued reports on Immunovia AB (publ) in the last year: Danske.
View the latest analyst ratings for IMMVF.

What is the current price target for Immunovia AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Immunovia AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Immunovia AB (publ) in the next year.
View the latest price targets for IMMVF.

What is the current consensus analyst rating for Immunovia AB (publ)?

Immunovia AB (publ) currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMMVF will outperform the market and that investors should add to their positions of Immunovia AB (publ).
View the latest ratings for IMMVF.

What other companies compete with Immunovia AB (publ)?

How do I contact Immunovia AB (publ)'s investor relations team?

The company's listed phone number is (902) 492-1819. The official website for Immunovia AB (publ) is www.imvaccine.com.